Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Chatelut

Showing results (41-50 of 77) with videos related to

Pageof 8
Sort By:
European Journal of Cancer (Oxford, England : 1990)|October 1, 1995
Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patientsB Peng, A V Boddy, M Cole, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1993
Extended CSF cytarabine exposure following intrathecal administration of DTC 101S Kim, E Chatelut, J C Kim, et al.
Bulletin Du Cancer|September 8, 1999
[Intraperitoneal high dose chemotherapy as consolidation treatment for advanced ovarian carcinoma: a pilot study]L Gladieff, E Chatelut, M H Gaspard, et al.
European Journal of Cancer (Oxford, England : 1990)|December 26, 2001
Impact of the biochemical assay for serum creatinine measurement on the individual carboplatin dosing: a prospective studyF Léger, S Séronie-Vivien, J Makdessi, et al.
Pharmacological Research|May 15, 2016
Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatinC Sauzay, M White-Koning, I Hennebelle, et al.
Journal of the National Cancer Institute|April 19, 1995
Prediction of carboplatin clearance from standard morphological and biological patient characteristicsE Chatelut, P Canal, V Brunner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1994
Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantationM Attal, P Canal, D Schlaifer, et al.
European Journal of Clinical Pharmacology|September 11, 2001
Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in childrenA Patoux, N Bleyzac, A V Boddy, et al.
American Journal of Clinical Oncology|February 1, 1997
Radiotherapy with concomitant continuous cisplatin infusion for unresectable tumors of the upper aerodigestive tract: results of a phase I studyJ M Bachaud, E Chatelut, P Canal, et al.
Bulletin Du Cancer|November 1, 1995
[Prediction of carboplatin clearance from morphological and biological patient characteristics]E Chatelut, A Dezeuze, M Lavit, et al.
Pageof 8

Showing results (41-50 of 77) with videos related to

Sort By:
Pageof 8
European Journal of Cancer (Oxford, England : 1990)|October 1, 1995
Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patientsB Peng, A V Boddy, M Cole, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1993
Extended CSF cytarabine exposure following intrathecal administration of DTC 101S Kim, E Chatelut, J C Kim, et al.
Bulletin Du Cancer|September 8, 1999
[Intraperitoneal high dose chemotherapy as consolidation treatment for advanced ovarian carcinoma: a pilot study]L Gladieff, E Chatelut, M H Gaspard, et al.
European Journal of Cancer (Oxford, England : 1990)|December 26, 2001
Impact of the biochemical assay for serum creatinine measurement on the individual carboplatin dosing: a prospective studyF Léger, S Séronie-Vivien, J Makdessi, et al.
Pharmacological Research|May 15, 2016
Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatinC Sauzay, M White-Koning, I Hennebelle, et al.
Journal of the National Cancer Institute|April 19, 1995
Prediction of carboplatin clearance from standard morphological and biological patient characteristicsE Chatelut, P Canal, V Brunner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1994
Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantationM Attal, P Canal, D Schlaifer, et al.
European Journal of Clinical Pharmacology|September 11, 2001
Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in childrenA Patoux, N Bleyzac, A V Boddy, et al.
American Journal of Clinical Oncology|February 1, 1997
Radiotherapy with concomitant continuous cisplatin infusion for unresectable tumors of the upper aerodigestive tract: results of a phase I studyJ M Bachaud, E Chatelut, P Canal, et al.
Bulletin Du Cancer|November 1, 1995
[Prediction of carboplatin clearance from morphological and biological patient characteristics]E Chatelut, A Dezeuze, M Lavit, et al.
Pageof 8